---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:18:08.207219'
end_time: '2026-02-14T14:23:37.037144'
duration_seconds: 328.83
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: STAT4
  gene_symbol: STAT4
  uniprot_accession: Q14765
  protein_description: 'RecName: Full=Signal transducer and activator of transcription
    4;'
  gene_info: Name=STAT4;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the transcription factor STAT family.
  protein_domains: p53-like_TF_DNA-bd_sf. (IPR008967); SH2. (IPR000980); SH2_dom_sf.
    (IPR036860); STAT. (IPR001217); STAT4_CC. (IPR046991)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 15
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q14765
- **Protein Description:** RecName: Full=Signal transducer and activator of transcription 4;
- **Gene Information:** Name=STAT4;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the transcription factor STAT family.
- **Key Domains:** p53-like_TF_DNA-bd_sf. (IPR008967); SH2. (IPR000980); SH2_dom_sf. (IPR036860); STAT. (IPR001217); STAT4_CC. (IPR046991)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "STAT4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'STAT4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **STAT4** (gene ID: STAT4, UniProt: Q14765) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q14765
- **Protein Description:** RecName: Full=Signal transducer and activator of transcription 4;
- **Gene Information:** Name=STAT4;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the transcription factor STAT family.
- **Key Domains:** p53-like_TF_DNA-bd_sf. (IPR008967); SH2. (IPR000980); SH2_dom_sf. (IPR036860); STAT. (IPR001217); STAT4_CC. (IPR046991)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "STAT4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'STAT4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **STAT4** (gene ID: STAT4, UniProt: Q14765) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and identity verification
- Target checked: STAT4 (signal transducer and activator of transcription 4), UniProt Q14765, human. Literature confirms STAT4 is a STAT-family transcription factor with N-terminal domain (NTD), coiled-coil domain (CCD), DNA-binding domain (DBD), linker domain (LD), SH2 domain, and C‑terminal transactivation domain (TAD), consistent with UniProt/domain annotations provided. Activation is via cytokine receptors through JAK2/TYK2, leading to STAT4 Tyr693 phosphorylation, dimerization, and nuclear translocation; serine phosphorylation modulates full transcriptional activity. These features align with the p53-like DNA-binding fold and SH2 domain noted in the brief (Frontiers in Immunology, Nov 2024; DOI: 10.3389/fimmu.2024.1479418). (xia2024stat4genepolymorphisms pages 1-2, xia2024stat4genepolymorphisms pages 2-4)

Comprehensive research report on STAT4 (Human; UniProt Q14765)

1) Key concepts and definitions with current understanding
- Molecular identity and domains: STAT4 is a latent cytoplasmic transcription factor of the STAT family (human STAT4 ~748 aa), comprising NTD, CCD, DBD, LD, SH2, and a C‑terminal TAD. Two splice isoforms exist: STAT4a (with TAD) and STAT4b (lacking TAD), with functional differences in transcriptional potency. URL: https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024). (xia2024stat4genepolymorphisms pages 1-2)
- Activation mechanism: Cytokine engagement (notably IL‑12 and, context-dependently in human cells, IL‑23 and type I IFNs) activates receptor-associated JAK2/TYK2, which phosphorylate STAT4 on tyrosine (Y693), enabling SH2-mediated dimerization, nuclear translocation, and target-gene activation. p38/MKK6-mediated serine phosphorylation (e.g., S721) augments transcriptional output. URL: https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024). (xia2024stat4genepolymorphisms pages 2-4, xia2024stat4genepolymorphisms pages 1-2)
- Pathway placement: STAT4 is the canonical effector of IL‑12 signaling and can be engaged by IL‑23 in specific myeloid contexts, placing it centrally in type 1 immunity circuits that program Th1 responses and related cell functions. URL: https://doi.org/10.1073/pnas.2400153121 (PNAS, Aug 2024). (alakhras2024anil23stat4pathway pages 1-2)
- Subcellular localization: STAT4 is cytosolic in resting cells and translocates to the nucleus upon phosphorylation/dimerization to bind DNA and regulate transcription. URL: https://doi.org/10.34172/bi.30030 (BioImpacts, May 2024). (sohrabi2024statsignalingpathways pages 1-2)
- Principal immune cell types: STAT4 is essential in CD4+ T helper 1 (Th1) differentiation and participates in T follicular helper/regulatory programs (Tfh/Tfr); it is active in NK cells, CD8+ T cells, and mature/activated dendritic cells (DCs), with inducible expression in certain myeloid cells. URLs: https://doi.org/10.1126/sciimmunol.adf2047 (Science Immunology, Jul 2024); https://doi.org/10.1073/pnas.2400153121 (PNAS, Aug 2024); https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024). (castano2024il12drivesthe pages 1-1, alakhras2024anil23stat4pathway pages 1-2, xia2024stat4genepolymorphisms pages 1-2, xia2024stat4genepolymorphisms pages 10-10)
- Canonical target genes and programs: STAT4 drives Th1-associated gene expression, including induction of IL12RB2 and IFNG, and cooperates with chromatin-remodeling machinery during Th1 differentiation. URL: https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024). (xia2024stat4genepolymorphisms pages 10-10)

2) Recent developments and latest research (2023–2024 prioritized)
- IL‑12/STAT4 programs T follicular regulatory (Tfr) cells in humans: Low-dose IL‑12 induces Tfr differentiation from activated human Treg cells while preserving suppressive function; mechanistically, IL‑12 triggers STAT4 phosphorylation and STAT4 binding at follicular signature loci. Patients with IL12RB1 deficiency exhibit markedly decreased circulating Tfr cells and elevated anti‑actin autoantibodies in vivo, supporting a physiological IL‑12→STAT4 axis in human Tfr biology. URL: https://doi.org/10.1126/sciimmunol.adf2047 (Science Immunology, Jul 2024). (castano2024il12drivesthe pages 1-1)
- IL‑23→STAT4 signaling in dendritic cells is IL‑12‑independent and required for CNS autoimmunity: Conditional STAT4 deletion in CD11c+ DCs reduces T‑cell priming and CNS inflammation in EAE; DC intrinsic IL‑23R and STAT4 are necessary for the proinflammatory DC program, revealing an IL‑23→STAT4 pathway in myeloid cells with human MS-relevant signatures. URL: https://doi.org/10.1073/pnas.2400153121 (PNAS, Aug 2024). (alakhras2024anil23stat4pathway pages 1-2)
- Chromatin/epigenomic placement in Th1 differentiation: STAT4 cooperates with SWI/SNF-like BAF chromatin remodeling to induce IL12RB2 during human Th1 differentiation, confirming its role as a lineage-defining factor within Th1 epigenomic programs. URL: https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024; citing EMBO J. 2007 mechanistic work contextualized in 2024 review). (xia2024stat4genepolymorphisms pages 10-10)
- Selective JAK pathway modulation and T cell phenotypes in SLE: In ex vivo human assays, IL‑12 induces STAT1/STAT4 phosphorylation and Tfh1 differentiation; TYK2 inhibition suppresses IL‑12–driven Tfh1 while sparing IL‑2→STAT5 signaling and Treg differentiation, unlike broader JAK inhibitors. This supports pharmacologic strategies that dampen IL‑12/STAT4 axes while preserving Treg biology. URL: https://doi.org/10.1136/rmdopen-2023-003991 (RMD Open, Jun 2024). (satohkanda2024modifyingtcell pages 1-1)

3) Current applications and real-world implementations
- Therapeutic pathway targeting: Given STAT4’s centrality to IL‑12 and IL‑23 circuits, upstream blockade with TYK2-selective inhibitors can reduce IL‑12–dependent STAT4 activation in human T cells (Tfh1) while preserving IL‑2/STAT5‑dependent Treg differentiation, highlighting a therapeutic window explored in SLE drug development (including progressing clinical programs referenced by investigators). URL: https://doi.org/10.1136/rmdopen-2023-003991 (RMD Open, Jun 2024). (satohkanda2024modifyingtcell pages 1-1)
- Innate/adaptive immune interface: The discovery that IL‑23 directly activates STAT4 within DCs (independently of IL‑12) suggests that part of the clinical benefit of IL‑23 blockade in inflammatory diseases may derive from interrupting a STAT4‑dependent DC inflammatory program, beyond effects on Th17/Tc17 circuits. URL: https://doi.org/10.1073/pnas.2400153121 (PNAS, Aug 2024). (alakhras2024anil23stat4pathway pages 1-2)

4) Expert opinions and analysis from authoritative sources
- Consensus on STAT4 biology and domain/function relationships: A recent comprehensive review synthesizes STAT4’s domain architecture, activation mechanisms (JAK2/TYK2; Tyr693; serine phosphorylation), cell-type specificity, and disease genetics, underscoring its central role in human type 1 immunity and autoimmunity. URL: https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024). (xia2024stat4genepolymorphisms pages 1-2, xia2024stat4genepolymorphisms pages 10-10)
- General Jak/STAT pathway mechanics and therapeutic context: Contemporary reviews reaffirm Jak-mediated STAT activation, SH2-driven dimerization, and nuclear signaling as common to most immune cells and highlight the clinical emergence of JAK pathway inhibitors across immune-mediated diseases, providing mechanistic rationale for upstream STAT4-pathway modulation. URL: https://doi.org/10.34172/bi.30030 (BioImpacts, May 2024). (sohrabi2024statsignalingpathways pages 1-2)

5) Relevant statistics and data from recent studies
- Human Tfr differentiation depends on IL‑12→STAT4: IL‑12 exposure phosphorylates STAT4 and recruits STAT4 to follicular signature genes in activated human Treg cells; individuals with IL12RB1 inborn errors show a “strong decrease” in circulating Tfr cells and increased anti‑actin autoantibodies, providing in vivo human evidence of pathway relevance. URL: https://doi.org/10.1126/sciimmunol.adf2047 (Science Immunology, Jul 2024). (castano2024il12drivesthe pages 1-1)
- IL‑23→STAT4 in DCs is necessary for CNS autoimmune inflammation: Genetic ablation of STAT4 in CD11c+ DCs reduces T‑cell priming and EAE severity, and adoptive studies show that wild-type DCs are sufficient to restore disease susceptibility whereas IL‑23R‑ or STAT4‑deficient DCs are not, defining a mechanistic IL‑23→STAT4 DC axis. URL: https://doi.org/10.1073/pnas.2400153121 (PNAS, Aug 2024). (alakhras2024anil23stat4pathway pages 1-2)
- Population-level associations for rs7574865 in RA (Mexico): In a Western Mexican cohort, the rs7574865 T allele (dominant/additive models) associated with RA susceptibility (OR ~1.92) and with higher disease activity (DAS28) and anti‑CCP positivity; no association observed in a Southern Mexican cohort, pointing to population heterogeneity. URL: https://doi.org/10.3390/genes15020241 (Genes, Feb 2024). (bravovillagra2024stat4genevariant pages 10-11)
- Cross-disease and functional genetics of STAT4 variants: Reviews/meta-analyses collate strong associations of STAT4 intronic variants—especially rs7574865[T]—with RA and SLE across multiple ancestries; functional correlations include increased STAT4 mRNA/protein and higher IL‑12‑induced IFN‑γ/pSTAT4 responses in SLE patient T cells carrying the risk allele. URLs: https://doi.org/10.3389/fimmu.2024.1479418 (Frontiers in Immunology, Nov 2024). (xia2024stat4genepolymorphisms pages 5-6, xia2024stat4genepolymorphisms pages 10-10, xia2024stat4genepolymorphisms pages 4-5, xia2024stat4genepolymorphisms pages 13-13)
- Pathway pharmacology in human cells: TYK2 inhibition in memory CD4+ T cells reduced IL‑12–induced pSTAT1/4 and Tfh1 differentiation, but spared IL‑2→pSTAT5 and Treg differentiation, suggesting a strategy to selectively suppress pathogenic IL‑12/STAT4 programs while preserving regulatory circuits. URL: https://doi.org/10.1136/rmdopen-2023-003991 (RMD Open, Jun 2024). (satohkanda2024modifyingtcell pages 1-1)

Focused functional role, localization, and pathway context
- Primary function: STAT4 is a cytokine-activated transcription factor that transduces IL‑12 family and (contextually) type I IFN signals to the nucleus to enforce type 1 immune transcriptional programs. In CD4+ T cells, it is required for Th1 differentiation; in Treg cells, IL‑12/STAT4 can program a Tfr phenotype; in myeloid DCs, STAT4 drives an IL‑23–dependent proinflammatory program crucial for T‑cell priming in CNS autoimmunity. URLs: https://doi.org/10.1126/sciimmunol.adf2047 (Jul 2024); https://doi.org/10.1073/pnas.2400153121 (Aug 2024). (castano2024il12drivesthe pages 1-1, alakhras2024anil23stat4pathway pages 1-2)
- Subcellular site of action: STAT4 operates in the cytosol-to-nucleus axis; upon activation, it dimerizes and translocates to the nucleus to bind DNA via its DBD and recruit co-regulators via its TAD to drive gene expression. URL: https://doi.org/10.34172/bi.30030 (May 2024). (sohrabi2024statsignalingpathways pages 1-2)
- Pathway crosstalk: The strength and cytokine context (IL‑12 vs IL‑23 vs IFN‑α/β) determine STAT4 engagement across cell types, with JAK2/TYK2 as key upstream kinases and SOCS proteins (e.g., SOCS3) serving as negative regulators. URL: https://doi.org/10.3389/fimmu.2024.1479418 (Nov 2024). (xia2024stat4genepolymorphisms pages 13-13)

Notes on evidence scope and open questions
- Cancer immunity/PD‑L1 regulation: While emerging studies propose tumor-intrinsic and immune-context roles for STAT4, dedicated 2023–2024 mechanistic evidence specifically linking STAT4 to PD‑L1 regulation and immunotherapy biomarkers in human cancers requires direct citation beyond the present evidence set and should be interpreted cautiously pending additional primary data. (sohrabi2024statsignalingpathways pages 1-2)
- Clinical trials: Multiple agents act upstream of STAT4 (e.g., TYK2 inhibitors; IL‑23 antagonists), but specific trial registrations and statuses are not detailed in the current evidence set; translational implications can be inferred from human ex vivo pharmacology demonstrating selective suppression of IL‑12/STAT4 programs with TYK2 inhibition. (satohkanda2024modifyingtcell pages 1-1)

Conclusion
Human STAT4 (UniProt Q14765) is a STAT-family transcription factor with SH2 and DNA-binding domains that transduces IL‑12 family cytokine signals via JAK2/TYK2 to orchestrate Th1/Tfr programs in lymphocytes and proinflammatory programs in dendritic cells. Recent 2024 studies expand STAT4’s functional reach to IL‑23–driven DC biology in CNS inflammation and establish a human IL‑12→STAT4 axis instructing Tfr differentiation. Genetic evidence consolidates rs7574865 and related intronic variants as risk factors for RA/SLE across ancestries, with functional correlates in STAT4 expression and IL‑12 responsiveness. Pharmacologic data in human cells show that TYK2‑selective inhibition can suppress IL‑12/STAT4 signaling while preserving IL‑2/STAT5 and Treg biology, supporting pathway‑tuned therapeutic strategies. URLs and dates have been provided where available. (alakhras2024anil23stat4pathway pages 1-2, castano2024il12drivesthe pages 1-1, satohkanda2024modifyingtcell pages 1-1, xia2024stat4genepolymorphisms pages 1-2, xia2024stat4genepolymorphisms pages 10-10, sohrabi2024statsignalingpathways pages 1-2, xia2024stat4genepolymorphisms pages 5-6, xia2024stat4genepolymorphisms pages 4-5, xia2024stat4genepolymorphisms pages 13-13, bravovillagra2024stat4genevariant pages 10-11)

References

1. (xia2024stat4genepolymorphisms pages 1-2): Yan Xia, Yanni Xie, Hao Zhang, and Lunzhi Liu. Stat4 gene polymorphisms in human diseases. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1479418, doi:10.3389/fimmu.2024.1479418. This article has 9 citations and is from a peer-reviewed journal.

2. (xia2024stat4genepolymorphisms pages 2-4): Yan Xia, Yanni Xie, Hao Zhang, and Lunzhi Liu. Stat4 gene polymorphisms in human diseases. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1479418, doi:10.3389/fimmu.2024.1479418. This article has 9 citations and is from a peer-reviewed journal.

3. (alakhras2024anil23stat4pathway pages 1-2): Nada S. Alakhras, Wenwu Zhang, Nicolas Barros, Anchal Sharma, James Ropa, Raj Priya, X. Frank Yang, and Mark H. Kaplan. An il-23-stat4 pathway is required for the proinflammatory function of classical dendritic cells during cns inflammation. Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2400153121, doi:10.1073/pnas.2400153121. This article has 5 citations and is from a highest quality peer-reviewed journal.

4. (sohrabi2024statsignalingpathways pages 1-2): Sepideh Sohrabi, Shiva Alipour, Zahra Ghahramanipour, Javad Masoumi, and Behzad Baradaran. Stat signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis. BioImpacts : BI, May 2024. URL: https://doi.org/10.34172/bi.30030, doi:10.34172/bi.30030. This article has 11 citations.

5. (castano2024il12drivesthe pages 1-1): Diana Castaño, Sidney Wang, Segovia Atencio-Garcia, Emily J. Shields, Maria C. Rico, Hannah Sharpe, Jacinta Bustamante, Allan Feng, Carole Le Coz, Neil Romberg, John W. Tobias, Paul J. Utz, Sarah E. Henrickson, Jean-Laurent Casanova, Roberto Bonasio, and Michela Locci. Il-12 drives the differentiation of human t follicular regulatory cells. Science Immunology, Jul 2024. URL: https://doi.org/10.1126/sciimmunol.adf2047, doi:10.1126/sciimmunol.adf2047. This article has 14 citations and is from a highest quality peer-reviewed journal.

6. (xia2024stat4genepolymorphisms pages 10-10): Yan Xia, Yanni Xie, Hao Zhang, and Lunzhi Liu. Stat4 gene polymorphisms in human diseases. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1479418, doi:10.3389/fimmu.2024.1479418. This article has 9 citations and is from a peer-reviewed journal.

7. (satohkanda2024modifyingtcell pages 1-1): Yurie Satoh-Kanda, Shingo Nakayamada, Satoshi Kubo, Kaoru Yamagata, Aya Nawata, Hiroaki Tanaka, Shunpei Kosaka, Ryuichiro Kanda, Shan Yu, Yuya Fujita, Koshiro Sonomoto, and Yoshiya Tanaka. Modifying t cell phenotypes using tyk2 inhibitor and its implications for the treatment of systemic lupus erythematosus. RMD Open, 10:e003991, Jun 2024. URL: https://doi.org/10.1136/rmdopen-2023-003991, doi:10.1136/rmdopen-2023-003991. This article has 13 citations and is from a peer-reviewed journal.

8. (bravovillagra2024stat4genevariant pages 10-11): Karla Mayela Bravo-Villagra, José Francisco Muñoz-Valle, Christian Johana Baños-Hernández, Sergio Cerpa-Cruz, José Eduardo Navarro-Zarza, Isela Parra-Rojas, José Alonso Aguilar-Velázquez, Samuel García-Arellano, and Andres López-Quintero. Stat4 gene variant rs7574865 is associated with rheumatoid arthritis activity and anti-ccp levels in the western but not in the southern population of mexico. Genes, 15:241, Feb 2024. URL: https://doi.org/10.3390/genes15020241, doi:10.3390/genes15020241. This article has 16 citations and is from a poor quality or predatory journal.

9. (xia2024stat4genepolymorphisms pages 5-6): Yan Xia, Yanni Xie, Hao Zhang, and Lunzhi Liu. Stat4 gene polymorphisms in human diseases. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1479418, doi:10.3389/fimmu.2024.1479418. This article has 9 citations and is from a peer-reviewed journal.

10. (xia2024stat4genepolymorphisms pages 4-5): Yan Xia, Yanni Xie, Hao Zhang, and Lunzhi Liu. Stat4 gene polymorphisms in human diseases. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1479418, doi:10.3389/fimmu.2024.1479418. This article has 9 citations and is from a peer-reviewed journal.

11. (xia2024stat4genepolymorphisms pages 13-13): Yan Xia, Yanni Xie, Hao Zhang, and Lunzhi Liu. Stat4 gene polymorphisms in human diseases. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1479418, doi:10.3389/fimmu.2024.1479418. This article has 9 citations and is from a peer-reviewed journal.

## Citations

1. sohrabi2024statsignalingpathways pages 1-2
2. satohkanda2024modifyingtcell pages 1-1
3. T
4. https://doi.org/10.3389/fimmu.2024.1479418
5. https://doi.org/10.1073/pnas.2400153121
6. https://doi.org/10.34172/bi.30030
7. https://doi.org/10.1126/sciimmunol.adf2047
8. https://doi.org/10.1136/rmdopen-2023-003991
9. https://doi.org/10.3390/genes15020241
10. https://doi.org/10.3389/fimmu.2024.1479418,
11. https://doi.org/10.1073/pnas.2400153121,
12. https://doi.org/10.34172/bi.30030,
13. https://doi.org/10.1126/sciimmunol.adf2047,
14. https://doi.org/10.1136/rmdopen-2023-003991,
15. https://doi.org/10.3390/genes15020241,